Clopidogrel in the treatment and prophylaxis of cerebrovascular diseases


Cite item

Full Text

Abstract

We consider the possibility of modern antiplatelets use such as clopidogrel in the treatment and prevention of acute disorders of cerebral circulation. According to the multicenter clinical studies database, antiplatelet therapy effectively prevents stroke, myocardial infarction and mortality from cardiovascular causes in patients with symptomatic atherosclerosis. The complexity of clopidogrel action (antiplatelet, hemangiocorrective, lipid-lowering activity) along with its high clinical efficacy can recommend this drug to a wide range of patients with ischemic cerebrovascular diseases: in the secondary prevention of thrombotic events in patients with multiple lesions of the vascular system; in the secondary ischemic stroke prevention and after reparative surgeries on the carotid arteries.

References

  1. Варакин Ю.Я. Эпидемиологические аспекты профилактики нарушений мозгового кровообращения // Атмосфера. Нервные болезни. 2005. № 2. С. 4-10.
  2. Домашенко М.А. Дисфункция эндотелия в остром периоде ишемического нсульта. Дисс. канд. мед. наук. М., 2006.
  3. Инсульт. Диагностика, лечение и профилактика. Руководство для врачей / Под ред. З.А. Суслиной, М.А. Пирадова. М., 2008.
  4. Карпов Ю.А., Сорокин Е.В. Интенсивное медикаментозное лечение больных с атеросклерозом // Кардиология. 2005. № 8. С. 4-7.
  5. Комаров А.Л., Панченко Е.П. Роль воспаления в развитии атеротромбоза: "противовоспалительные" эффекты клопидогрела // Фарматека. 2007. № 8/9. С. 23-29.
  6. Очерки ангионеврологии / Под ред. З.А. Суслиной. М., 2005.
  7. Суслина З.А. Ишемические нарушения мозгового кровообращения и система простаноидов (клинико-биохимическое исследование). Дисс. докт. мед. наук. М., 1990.
  8. Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка и антитромботическая терапия. М., 2005.
  9. Суслина З.А., Танашян М.М., Ионова В.Г. Концепция дизрегуляции гемостаза как универсального фактора патогенеза ишемического инсульта. Материалы IX всероссийского съезда неврологов. 2006. С. 489.
  10. Суслина З.А. и др. Клопидогрель при ишемических цереброваскулярных заболеваниях // Лечение нервных болезней. 2003. № 4. С. 14-18.
  11. Танашян М.М. и др. Гемангиокорректорная эффективность Плавикса у больных с церебральной ишемией // Атмосфера. Нервные болезни. 2005. № 3. С. 2-7.
  12. Танашян М.М. Ишемические инсульты и основные характеристики гемореологии, гемостаза и фибринолиза. Дисс. докт. мед. наук. М., 1997.
  13. Танашян М.М. и др. Особенности лечения больных с цереброваскулярными заболеваниями на фоне метаболического синдрома // Атмосфера. Нервные болезни. 2006. № 1. С. 12-16.
  14. Танашян М.М. и др. Состояние функции эндотелия у больных с ишемическим инсультом при различной степени атеросклеротического поражения сонных артерий // Неврологический вестник. 2007. Т. XXXIX. Вып. 1. С. 12-16.
  15. Alberts MJ. Secondary prevention of stroke and the expanding role of the neurologist. Cerebrovasc Dis 2002;13(Suppl. 1):12-16.
  16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
  17. Atlas of Atherothrombosis. Edit. in-Chief Topol E.J. Science Press, UK, 2004.
  18. Bertrand ME, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-29.
  19. Bhatt DL, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-28.
  20. Bhatt DL, et al Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
  21. Bhatt DL, et al. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. J Am Coll Cardiol 2007;49:1982-88.
  22. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev 2003;2(1):15-28.
  23. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;6:939-43.
  24. Buhk J-F, et al. Late in-stent thrombosis following carotid angioplasty and stenting. Neurology 2006;66:1594-96.
  25. Caplain H. Enhanced antiplatelet effects of clopidogrel plus ASA compared with ASA alone or with extended release dipyridamole combined with low-dose ASA in healthy volunteers. Cerebrovasc Dis 2001;11(Suppl. 4):85.
  26. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329-39.
  27. Chew DP, et al Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-74.
  28. Diener HC, et al. Aspirin and clopidogrel compared with clopidogrel alone after ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004;34:331-37.
  29. Diener HC, et al. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PPoFESS). Cerebrovasc Dis 2007;23:368-80.
  30. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008 http://www.eso-stroke.org/recommendations
  31. Harker LA, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Safety 1999;21:325-35.
  32. Kennedy J, et al. 2007 Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence Trial (FASTER): a randomized controlled pilot trial. Lancet Neurol 2007;6(11):961-69.
  33. MacDonald BK, Cockerell OC, Sander JWAS, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-76.
  34. McKevitt FM, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005;29:522-27.
  35. PRoFESS: обзор результатов http://www.medscape.com/viewarticle/574558
  36. Ringleb PA, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528-32.
  37. Sacco RL, et al. Guidelenes for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006;37:577-617.
  38. Serebruany VL, et al. Effects of Clopidogrel and Aspirin in Combination versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke. Stroke 2005;36:2289-92.
  39. The Clopidogrel in Unstable Angina to Prevent Recurrent Event Trial Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
  40. th European Stroke Conference, Nice, France. Cerebrovasc Dis 2008;25(Suppl. 2).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies